Drug profile · INN
brivaracetam
BRIVIACT
brivaracetam (BRIVIACT) is a synaptic vesicle glycoprotein 2a modulator. Associated with Sunshine Guojian Pharmaceutical (Shanghai) Co.,. Route of administration: oral. Current US regulatory status: approved.
Drug details — brivaracetam
- US status
- approved
- Class
- Nervous system (N03)
- Route
- ORAL
- Patents
- 20
- Programs
- 4
- Data quality
- 0.89
Quick answer
brivaracetam (BRIVIACT) is a synaptic vesicle glycoprotein 2a modulator. Associated with Sunshine Guojian Pharmaceutical (Shanghai) Co.,. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Synaptic vesicle glycoprotein 2A modulator
Primary target: Synaptic vesicle glycoprotein 2A
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
-
US 12428389
Diarylamide compound and application thereof
granted -
US 12258317
Isoquinolinone compound for inhibiting ssao/vap-1, and use thereof
granted -
US 12194065
Methods and compositions to enhance metabolic detoxification systems
granted -
US 12171761
Vilazodone inclusion complexes, compositions and preparation thereof
granted -
US 12128044
Fused tricyclic compounds and uses thereof in medicine
granted -
US 11679143
FGF21 variant, fusion protein and application thereof
granted -
US 11517569
Vilazodone inclusion complexes, compositions and preparation thereof
granted -
US 11447498
Fused tetracyclic compounds and uses thereof in medicine
granted -
US 11396495
Amine compound for inhibiting SSAO/VAP-1 and use thereof
granted -
US 11285153
Substituted pyrimidine piperazine compound and use thereof
granted -
US 11261190
Dihydropyrimidine compounds and uses thereof in medicine
granted -
US 11242335
Fluorine-substituted indazole compounds and uses thereof
granted -
US 11142527
Dihydropyrimidine compounds and uses thereof in medicine
granted -
US 11122832
Methods and compositions to improve weight loss and cardiometabolic health beyond diet and excercise
granted -
US 10966970
Fused tricyclic compounds and uses thereof in medicine
granted -
US 10927089
Diaryl thioether piperazine compounds, preparation methods and uses thereof
granted -
US 10751339
Substituted aminopyrimidine compounds and methods of use
granted -
US 10688090
Vilazodone inclusion complexes, compositions and preparation thereof
granted -
US 10316025
Substituted piperazine compounds and methods of use and use thereof
granted -
US 10266521
Substituted heteroaryl compounds and methods of use
granted
Frequently asked questions
What is brivaracetam?
brivaracetam (BRIVIACT) is a synaptic vesicle glycoprotein 2a modulator. Associated with Sunshine Guojian Pharmaceutical (Shanghai) Co.,. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for brivaracetam?
BRIVIACT is a marketed brand name for brivaracetam. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of brivaracetam?
brivaracetam has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.